Scientists on the Florida campus of The Scripps Research Institute (TSRI) have improved a state-of-the-art gene-editing technology to advance the system’s ability to target, cut and paste genes within human and animal cells—and broadening the ways the CRISPR-Cpf1 editing system may be used to study and fight human diseases.
Professor Michael Farzan, co-chair of TSRI’s Department of Immunology and Microbiology, and TSRI Research Associate Guocai Zhong improved the efficiency of the CRISPR-Cpf1 gene editing system by incorporating guide RNAs with “multiplexing” capability. Guide RNAs are short nucleic acid strings that lead the CRISPR molecular scissors to their intended gene targets. The TSRI discovery means multiple genetic targets in a cell may be hit by each CRISPR-Cpf1 complex.
“This system simplifies and significantly improves the efficiency of simultaneous editing of multiple genes, or multiple sites of a single gene,” Zhong said. “This could be very useful when multiple disease-related genes or multiple sites of a disease-related gene need to be targeted.”
“This approach improves gene editing for a number of applications,” Farzan added. “The system makes some applications more efficient and other applications possible.”
This study was published as an advanced online paper in the journal Nature Chemical Biology on June 19, 2017.
TSRI Advance Makes CRISPR More Efficient
Short for “Clustered Regularly Interspaced Short Palindromic Repeat,” the CRISPR gene editing system exploits an ancient bacterial immune defense process. Some microbes thwart viral infection by sequestering a piece of a virus’ foreign genetic material within its own DNA, to serve as a template. The next time the viral sequence is encountered by the microbe, it’s recognized immediately and cut up for disposal with the help of two types of RNA. Molecules called guide RNAs provide the map to the invader, and CRISPR effector proteins act as the scissors that cut it apart.
Over the last five years, the CRISPR gene editing system has revolutionized microbiology and renewed hopes that genetic engineering might eventually become a useful treatment for disease. But time has revealed the technology’s limitations. For one, gene therapy currently requires using a viral shell to serve as the delivery package for the therapeutic genetic material. The CRISPR molecule is simply too large to fit with multiple guide RNAs into the most popular and useful viral packaging system.
The new study from Farzan and colleagues helps solve this problem by letting scientists package multiple guide RNAs.
This advance could be important if gene therapy is to treat diseases such as hepatitis B, Farzan said. After infection, hepatitis B DNA sits in liver cells, slowly directing the production of new viruses, ultimately leading to liver damage, cirrhosis and even cancer. The improved CRISPR-Cpf1 system, with its ability to ‘multiplex,’ could more efficiently digest the viral DNA, before the liver is irrevocably damaged, he said.
“Efficiency is important. If you modify 25 cells in the liver, it is meaningless. But if you modify half the cells in the liver, that is powerful,” Farzan said. “There are other good cases—say muscular dystrophy—where if you can repair the gene in enough muscle cells, you can restore the muscle function.”
Two types of these molecular scissors are now being widely used for gene editing purposes: Cas9 and Cpf1. Farzan said he focused on Cpf1 because it is more precise in mammalian cells. The Cpf1 molecule they studied was sourced from two types of bacteria, Lachnospiraceae bacterium and Acidaminococus sp., whose activity has been previously studied in E. coli. A key property of these molecules is they are able to grab their guide RNAs out of a long string of such RNA; but it was not clear that it would work with RNA produced from mammalian cells. Guocai tested this idea by editing a firefly bioluminescence gene into the cell’s chromosome. The modified CRISPR-Cpf1 system worked as anticipated.
“This means we can use simpler delivery systems for directing the CRISPR effector protein plus guide RNAs,” Farzan said. “It’s going to make the CRISPR process more efficient for a variety of applications.”
Looking forward, Farzan said the Cpf1 protein needs to be more broadly understood so that its utility in delivering gene therapy vectors can be further expanded.
The Latest on: CRISPR-Cpf1
- In vivo profiling of metastatic double knockouts through CRISPR–Cpf1 screens on April 8, 2019 at 8:50 am
Systematic investigation of the genetic interactions that influence metastatic potential has been challenging. Here we developed massively parallel CRISPR–Cpf1/Cas12a crRNA array profiling (MCAP), an ... […]
- CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice on February 2, 2019 at 4:00 pm
1 Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 2 Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of ... […]
- BASF licenses CRISPR-Cpf1 from the Broad Institute of MIT and Harvard on October 24, 2018 at 8:09 am
RESEARCH TRIANGLE PARK, NC, October 24, 2018 - BASF has attained a global, non-exclusive licensing agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cpf1 genome editing ... […]
- Firefly gene illuminates ability of optimized CRISPR-Cpf1 to efficiently edit human genome on June 19, 2017 at 12:24 pm
The Scripps Research Institute. (2017, June 19). Firefly gene illuminates ability of optimized CRISPR-Cpf1 to efficiently edit human genome. ScienceDaily. Retrieved April 6, 2019 from www.sciencedaily ... […]
- Firefly gene illuminates ability of optimized CRISPR-Cpf1 to efficiently edit human genome on June 19, 2017 at 8:14 am
JUPITER, FL - June 19, 2017 - Scientists on the Florida campus of The Scripps Research Institute (TSRI) have improved a state-of-the-art gene-editing technology to advance the system's ability to ... […]
- Firefly gene illuminates ability of optimized CRISPR-Cpf1 to efficiently edit human genome on June 19, 2017 at 8:08 am
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have improved a state-of-the-art gene-editing technology to advance the system's ability to target, cut and paste genes within ... […]
- CRISPR Corrects Duchenne-Causing Mutations on April 12, 2017 at 11:12 am
Since germline gene editing cannot be applied to people with DMD, the team is next working on ways to deliver the CRISPR-Cpf1 gene edited cells to the relevant tissues in mice. The researchers are ... […]
- Broad Institute of MIT and Harvard to receive European patent for CRISPR-Cpf1 on February 28, 2017 at 10:28 pm
The Broad Institute of MIT and Harvard announced that based on a patent application filed in June 2015, the European Patent Office (EPO) will grant its first CRISPR-Cpf1 patent. CRISPR-Cpf1 holds the ... […]
- European Patent Office To Grant CRISPR-Cpf1 Patent To Broad Institute, MIT, And Harvard University on February 27, 2017 at 7:32 am
CAMBRIDGE, Mass., Feb. 27, 2017 /PRNewswire/ -- The European Patent Office (EPO) has announced it intends to grant its first CRISPR-Cpf1 patent to the Broad Institute, MIT, and Harvard University, ... […]
- Gene Editing Soybeans For Healthier Oil on February 22, 2017 at 10:56 pm
AsianScientist (Feb. 23, 2017) – Researchers have successfully edited two genes that control the fat content of soybean oil using CRISPR-Cpf1, an alternative to the more widely used gene editing tool ... […]
via Google News and Bing News